HealthEquity (HQY) is down ≈33% from its 52-week high, at 11% of the annual range, RSI 38. The trigger for looking: WEX's Q1 2026 10-Q, filed April 23, disclosed 484bps of net spread on $4.6B of HSA float at 0.11% weighted funding cost. That number validates the float math underpinning HQY's disclosed repricing ladder. Today's -6% tape is rate-sensitive flow dumping — the counterparty this thesis wants.

What the filings say

HQY's FY Jan 2026 10-K discloses a custodial cash repricing ladder: FY27 $4.5B at 1.9%, FY28 $2.3B at 4.0%, FY29 $1.7B at 3.6%, FY30 $2.4B at 4.4%, thereafter $6.4B at 4.2%. Weighted current yield 3.6%. Management has executed forward rate locks "above-market rates" on expiring Basic Rates contracts. FY Jan 2026 annualized yield was 3.53%, up from 3.11% YoY.

Mechanical FY27 lift: $4.5B × (4.0% – 1.9%) ≈ $94M gross revenue at ≈90% incremental margin on float. On ≈85M diluted shares, roughly $0.76 incremental EPS — against forward consensus EPS of ≈$5.34 (backed out from F-P/E 14.56 × current price), a ≈14% lift at unchanged multiple. Fed cuts of 50-100bps would dampen but not erase the spread: 1.9% sits well below any plausible terminal rate.

Cross-ticker anchor: WEX's Benefits segment earned 484bps on a fully-repriced $4.6B book last quarter. HQY runs 142bps below that level purely because its ladder hasn't rolled yet.

What the market thinks

Forward P/E 14.56. Mean analyst target $112.88; median $110; 14 buy/strong buy, 0 hold, 1 sell. Short float 4.7%. Options P/C OI 0.16 (bullish positioning, flat skew). Stock trades at 69% of analyst mean target — a ≈31% discount to sell-side consensus fair value. BMO downgraded to Market Perform ($105) on April 9.

Why the gap

The repricing is in a footnote and requires cross-referencing forward rate lock disclosures. Sell-side targets already sit 40-45% above current, so the gap isn't between us and analysts — it's between analysts and the marginal flow. Rate-sensitive sellers are trading the level (Fed will cut) rather than the vintage (1.9% locks reprice regardless). The edge is positioning, not information. The math is public. The marginal seller isn't reading the 10-K.

Risks (ranked)

1. Fed cuts ≥150bps by EOY 2026. Breaks the thesis. Current market pricing has ≈75bps.
2. Account migration to BofA/Fidelity/Optum teaser yields. Asset runoff would offset mechanical repricing. Unquantified — the biggest open gap.
3. Consensus already embeds the lift. Earnings surprises compressing (19.3% → 17.7% → 10.7% → 5.8% last four quarters) suggests analysts are catching up.
4. Management guides yield expectations down on Jun 2 call. Informed-counterparty signal.
5. Regulatory (HSA custodial cash rule change). Low probability, high magnitude.

Catalysts

• June 2, 2026: Q1 FY27 earnings. First read on repricing cadence. Threshold: annualized HSA WAC yield ≥3.65% confirms, <3.60% calls thesis into question.
• May 6-7, Jun 17-18, Jul 29-30, 2026: FOMC meetings, each a rate reprice.
• March 2027: FY Jan 2027 10-K — full repricing confirmation.

What would change our mind

• Q1 FY27 WAC yield prints <3.60% annualized on June 2
• Fed curve implies >100bps cuts by July FOMC
• Credible competitor account-migration data
• Management signals forward rate locks below 3.75%

Framing the trade

12-18 month probability-weighted scenarios:

Probability-weighted return ≈ +24%. Idio variance ≈ 88% (β-SPX 0.26 empirical) — no SPY hedge required. Pre-hedge Sharpe ≈0.55. Mid-conviction, not exceptional. Decision point is 8 business days out.

Evidence